Heart failure, chronic, systolic: Resynchronization using a biventricular pacemaker
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2005 Apr 14;352(15):1539-49 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic, having intraventricular conduction delays (QRS > 120 msec), non-pharmacological treatment The Use of
cardiac-resynchronization by biventricular stimulation with a pacemaker
As Treatment, Chronic
Is better Than
optimal pharmacologic therapy
To reduce hospitalisation for major cardiovascular event or death: 16%per year in resynchr. vs. 22,5% per year in non-resynchr. Included a significant reduction in mortality.
N Engl J Med. 2010 Dec 16;363(25):2385-95 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic, mild, having intraventricular conduction delays (QRS > 120 msec), non-pharmacological treatment The Use of
cardiac-resynchronization by biventricular stimulation added to an implantable cardioverter-defibrillator
As Treatment, Chronic
Is better Than
implantable cardioverter-defibrillator alone
To reduce at 40 months death or rehospitalization (40% resync VS 33% control) and reduce death (HR 0.75)
N Engl J Med. 2009 Oct 1;361(14):1329-38 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic, mild, having intraventricular conduction delays (QRS > 130 msec), non-pharmacological treatment The Use of
cardiac-resynchronization by biventricular stimulation with a pacemaker
As Treatment, Chronic
Is better Than
medical treatment
To reduce heart failure events at 2.5 years (10% resynchronization VS 18% no-resync). Mortality was unchanged.
N Engl J Med. 2014 May 1;370(18):1694-701 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic, mild, having left bundle-branch block, non-pharmacological treatment The Use of
cardiac-resynchronization by biventricular stimulation added to an implantable cardioverter-defibrillator
As Treatment, Chronic
Is better Than
implantable cardioverter-defibrillator alone
To reduce mrotality at 7 years: 18% resync VS 29% controls
N Engl J Med. 2004 May 20;350(21):2140-50 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic, severe, having intraventricular conduction delays (QRS > 120 msec), non-pharmacological treatment The Use of
cardiac-resynchronization by biventricular stimulation with a pacemaker
As Treatment, Chronic
Is better Than
optimal pharmacologic therapy alone (diuretics, ACE inhibitors, beta-blockers, and spironolactone)
To decrease the combined end point "death from any cause or hospitalization" and, when combined with an implantable defibrillator, decrease mortality. Difference not quantified in abstract.